Q1 Earnings Estimate for Glaukos Issued By William Blair

Glaukos Co. (NYSE:GKOS - Free Report) - Analysts at William Blair issued their Q1 2026 EPS estimates for shares of Glaukos in a report released on Thursday, May 1st. William Blair analyst M. Andrew expects that the medical instruments supplier will earn ($0.09) per share for the quarter. The consensus estimate for Glaukos' current full-year earnings is ($1.08) per share. William Blair also issued estimates for Glaukos' Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.19 EPS.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The business had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company's quarterly revenue was up 24.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.70) earnings per share.

Several other equities research analysts have also issued reports on the stock. Wells Fargo & Company lowered shares of Glaukos from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $160.00 to $86.00 in a report on Thursday, May 1st. Needham & Company LLC dropped their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Morgan Stanley cut their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday. Stephens decreased their price target on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Finally, Stifel Nicolaus cut their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Trading Up 0.1 %

NYSE GKOS traded up $0.09 on Monday, hitting $90.63. 104,389 shares of the stock were exchanged, compared to its average volume of 941,786. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a 52-week low of $77.10 and a 52-week high of $163.71. The firm has a market capitalization of $5.18 billion, a P/E ratio of -31.58 and a beta of 0.83. The stock has a fifty day moving average price of $95.31 and a two-hundred day moving average price of $127.64.

Insiders Place Their Bets

In other news, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Barclays PLC increased its holdings in shares of Glaukos by 394.4% during the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock valued at $11,686,000 after purchasing an additional 71,556 shares in the last quarter. Tidal Investments LLC grew its position in Glaukos by 83.1% during the third quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier's stock valued at $1,942,000 after buying an additional 6,767 shares during the period. Franklin Resources Inc. increased its holdings in Glaukos by 80.1% in the third quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier's stock valued at $2,031,000 after buying an additional 6,948 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Glaukos by 28.3% in the fourth quarter. GAMMA Investing LLC now owns 2,213 shares of the medical instruments supplier's stock worth $332,000 after acquiring an additional 488 shares during the period. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of Glaukos in the fourth quarter worth about $3,679,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.